Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Identifieur interne : 000308 ( Istex/Corpus ); précédent : 000307; suivant : 000309Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Auteurs : Lorraine V. Kalia ; Jonathan M. Brotchie ; Susan H. FoxSource :
- [ 0885-3185 ]
Abstract
Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic system to alter activity of the direct and indirect pathways. Many nondopaminergic neurotransmitter systems have been implicated in the mechanisms contributing to the motor features of Parkinson's disease (PD). Thus, it is now well established that neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of PD. Nondopaminergic neurotransmitter systems are thus targets for the development of novel therapies for motor symptoms and motor complications in PD. Over the last 5 years, more than 20 randomized, control trials (RCTs) in PD investigating drugs that target several of these nondopaminergic neurotransmitter systems for the treatment of motor features have been completed. There are at least 15 additional RCTs that are ongoing or planned. Here, we review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. © 2012 Movement Disorder Society
Url:
DOI: 10.1002/mds.25273
Links to Exploration step
ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FFLe document en format XML
<record><TEI wicri:istexFullTextTei="no"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials</title><author><name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sfox@uhnresearch.ca</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FF</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.25273</idno><idno type="url">https://api-v5.istex.fr/document/8E5F083D5F15E32FB9ACE93169C4835DB3C938FF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000308</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000308</idno></publicationStmt><sourceDesc><biblStruct><analytic><author><name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sfox@uhnresearch.ca</mods:affiliation></affiliation></author></analytic><series><idno type="ISSN">0885-3185</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic system to alter activity of the direct and indirect pathways. Many nondopaminergic neurotransmitter systems have been implicated in the mechanisms contributing to the motor features of Parkinson's disease (PD). Thus, it is now well established that neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of PD. Nondopaminergic neurotransmitter systems are thus targets for the development of novel therapies for motor symptoms and motor complications in PD. Over the last 5 years, more than 20 randomized, control trials (RCTs) in PD investigating drugs that target several of these nondopaminergic neurotransmitter systems for the treatment of motor features have been completed. There are at least 15 additional RCTs that are ongoing or planned. Here, we review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. © 2012 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Lorraine V. Kalia MD, PhD</name><affiliations><json:string>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</json:string><json:string>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Jonathan M. Brotchie PhD</name><affiliations><json:string>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Susan H. Fox MRCP(UK), PhD</name><affiliations><json:string>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</json:string><json:string>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</json:string><json:string>E-mail: sfox@uhnresearch.ca</json:string></affiliations></json:item></author><articleId><json:string>MDS25273</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic system to alter activity of the direct and indirect pathways. Many nondopaminergic neurotransmitter systems have been implicated in the mechanisms contributing to the motor features of Parkinson's disease (PD). Thus, it is now well established that neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of PD. Nondopaminergic neurotransmitter systems are thus targets for the development of novel therapies for motor symptoms and motor complications in PD. Over the last 5 years, more than 20 randomized, control trials (RCTs) in PD investigating drugs that target several of these nondopaminergic neurotransmitter systems for the treatment of motor features have been completed. There are at least 15 additional RCTs that are ongoing or planned. Here, we review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. © 2012 Movement Disorder Society</abstract><qualityIndicators><score>7.28</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1392</abstractCharCount><pdfWordCount>7376</pdfWordCount><pdfCharCount>50431</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>190</abstractWordCount></qualityIndicators><title>Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials</title><genre><json:string>review-article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>28</volume><issue>2</issue><pages><first>131</first><last>144</last><total>14</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Review</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1002/mds.25273</json:string></doi><id>8E5F083D5F15E32FB9ACE93169C4835DB3C938FF</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/8E5F083D5F15E32FB9ACE93169C4835DB3C938FF/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/8E5F083D5F15E32FB9ACE93169C4835DB3C938FF/fulltext/zip</uri></json:item><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/8E5F083D5F15E32FB9ACE93169C4835DB3C938FF/fulltext/txt</uri></json:item></fulltext><metadata><mods version="3.6"><titleInfo lang="en"><title>Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Nondopaminergic Targets for Motor Features of PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials</title></titleInfo><name type="personal"><namePart type="given">Lorraine V.</namePart><namePart type="family">Kalia</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jonathan M.</namePart><namePart type="family">Brotchie</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Susan H.</namePart><namePart type="family">Fox</namePart><namePart type="termsOfAddress">MRCP(UK), PhD</namePart><affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</affiliation><affiliation>E-mail: sfox@uhnresearch.ca</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2013-02</dateIssued><dateCreated encoding="w3cdtf">2013-02-20</dateCreated><dateCaptured encoding="w3cdtf">2012-08-15</dateCaptured><dateValid encoding="w3cdtf">2012-10-08</dateValid><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic system to alter activity of the direct and indirect pathways. Many nondopaminergic neurotransmitter systems have been implicated in the mechanisms contributing to the motor features of Parkinson's disease (PD). Thus, it is now well established that neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of PD. Nondopaminergic neurotransmitter systems are thus targets for the development of novel therapies for motor symptoms and motor complications in PD. Over the last 5 years, more than 20 randomized, control trials (RCTs) in PD investigating drugs that target several of these nondopaminergic neurotransmitter systems for the treatment of motor features have been completed. There are at least 15 additional RCTs that are ongoing or planned. Here, we review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. © 2012 Movement Disorder Society</abstract><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov Disord</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>131</start><end>144</end><total>14</total></extent></part></relatedItem><identifier type="istex">8E5F083D5F15E32FB9ACE93169C4835DB3C938FF</identifier><identifier type="DOI">10.1002/mds.25273</identifier><identifier type="ArticleID">MDS25273</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2012 Movement Disorders SocietyCopyright © 2012 Movement Disorders Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FF
|texte= Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
}}
| This area was generated with Dilib version V0.6.29. |  |